… inhibitors (TKIs) that target these … mutations in the EGFR that have been described in NSCLC
samples, and most cluster within the tyrosine kinase domain of this receptor tyrosine kinase…

… The importance of EGFR to lung cancers supports the … Tyrosine kinase inhibitors (TKIs)
have been used to treat the cancer harboring EGFR mutations or aberrant activation of EGFR. …

… Since the discovery of sensitizing EGFR mutations as a predictive marker of sensitivity to
EGFR tyrosine kinase inhibitors (TKIs), the field of targeted therapy in non-small cell lung …

… receptor tyrosine kinase inhibitors (EGFR-TKIs) improves the overall survival of patients with
EGFR-mutated … a secondary T790M mutation in addition to the active EGFR mutation may …

… tyrosine kinase domain of the receptor (… EGFR tyrosine kinase inhibitor (TKI), gefitinib,
compared with standard chemotherapy as first line therapy for patients harboring EGFR mutations […

… growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), … competitive inhibitors of the
tyrosine kinase domain of EGFR … EGFR mutations have led to strategies for novel EGFR TKIs …

… response to EGFR TKIs and the presence of EGFR mutations was confirmed in … EGFR
mutation status. This meta-analysis demonstrated that EGFR mutations predict response to EGFR …

… irreversible kinase inhibitors is significantly affected by mutation … can influence the EGFR
mutation spectrum induced by … dual inhibitor of epidermal growth factor receptor tyrosine kinases…

… growth factor receptor tyrosine kinase inhibitors erlotinib and … activating epidermal growth
factor receptor mutations. However, … EGFR TKIs is patients with activating EGFR mutations, …

… of differential responses to EGFR TKIs. Kinase domain of EGFR consists of a smaller N-…
reference of the sensitivity of uncommon EGFR mutations to EGFR-TKIs, we have identified …